Metastatic/Advanced Renal Cell Carcinoma Clinical Trial
Official title:
EVALUATION OF THE IMPACT OF A THERAPY MANAGEMENT PLATFORM ON THE MANAGEMENT OF PATIENTS SUFFERING FROM ADVANCED/METASTATIC RENAL CELL CARCINOMA AND RECEIVING FIRST LINE TREATMENT WITH SUNITINIB, VERSUS STANDARD FOLLOW-UP
100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib
(Sutent) will be inclued and followed with standard care plus a call center
Principal assumption : the proportion of patients presenting with at least one grade 3 or 4
AE (whether related to sunitinib or not).
RENACALL is a prospective intermediate care study whose main aim is to evaluate the impact of
a therapy management platform on the management of patients suffering from
advanced/metastatic renal cell carcinoma and receiving first line treatment with Sutent®.
100 mRCC patients treated receiving first line Sutent® treatment shall be included in the
study, and shall benefit both from conventional follow-up and from additional therapy
management platform-based follow-up. Platform follow-up shall consist in regular phone calls
to accompany patients in their real life home management of their treatment with sunitinib
(prevention, advice and guidance of patients towards options)..
;